Catecholamine/Serotonin Interactions
Open accessAbstract
This chapter brings together the work of several leading laboratories, each an outstanding example of integrative approaches to complex diseases of the central nervous system. Cognitive dysfunction and negative symptoms associated with schizophrenia are believed to result from hypofunction of the mesocortical dopaminergic projections to prefrontal cortex (PFC). Noradrenergic targets for the augmentation of dopaminergic function in PFC show promise to improve cognitive deficits as well as negative symptoms. Serotonergic targets for the modulation of mesocortical dopaminergic neurotransmission include 5-HT2A and 5-HT1A receptors. The hallmark of Parkinson's disease is the destruction of nigrostriatal dopaminergic neurons. l-DOPA, a metabolic precursor of dopamine, is the standard of treatment. However, the ectopic release of dopamine (DA) from serotonin neurons and the clearance of extracellular DA by the norepinephrine transporter in areas enriched with noradrenergic terminals contribute to extracellular DA produced by l-DOPA and offer opportunities to improve l-DOPA therapy. The high-affinity transporters for monoamines are the primary targets for antidepressant drugs. However, many patients experience suboptimal therapeutic benefit or fail to respond to treatment. Organic cation transporters and plasma membrane monoamine transporter serve an important function in regulating monoamine neurotransmission and hold potential utility as targets for the development of therapeutic drugs. Improved therapeutic approaches will arise from not only understanding how monoamines influence one another within the central nervous system as an integrated whole but also addressing the pathophysiology of specific core symptoms or distinct syndromal dimensions (cognitive impairment, motor slowing, and negative affect) regardless of disease classification, for example, psychotic, affective, and neurodegenerative.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
During embryonic development there is convergence of the various neurotransmitter signaling pathways and they influence each other's development and functioning.
“There is, furthermore, ample evidence now that during embryonic development there is convergence of the various neurotransmitter signaling pathways and influence each other’s development and functioning [153, 227–231].”
From Development of prefrontal cortex (2022) · cites this paper as [230]
The Introduction (page unavailable) describes overlapping innervation and functional interactions among dopamine, norepinephrine, and serotonin systems, supporting the claim that these pathways interact in brain function. It does not establish that they converge during embryonic development or influence one another’s development; searches for embryonic and developmental interactions found no such passage. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,388 · see citing works
Taussig, M. (1991) · Routledge eBooks · doi:10.4324/9780203397244 · Cited by 2,403 · see citing works
Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory
Vijayraghavan, S., Wang, M., Birnbaum, S. G., Williams, G. V., & Arnsten, A. F. T. (2007) · Nature Neuroscience · doi:10.1038/nn1846 · Cited by 1,013 · see citing works
Koepsell, H., Lips, K. S., & Volk, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9254-z · Cited by 984 · see citing works
Carr, D. B., & Sesack, S. R. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03864.2000 · Cited by 880 · see citing works
D1 receptors in prefrontal cells and circuits
Goldman-Rakic, P. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00045-4 · Cited by 807 · see citing works
DAncing past the DAT at a DA synapse
Cragg, S. J., & Rice, M. E. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.03.011 · Cited by 373 · see citing works
Eisenhofer, G. (2001) · Pharmacology and Therapeutics · doi:10.1016/s0163-7258(01)00144-9 · Cited by 373 · see citing works
Karreman, M., & Moghaddam, B. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66020589.x · Cited by 357 · see citing works
The history of dopamine and levodopa in the treatment of Parkinson's disease
Fahn, S. (2008) · Movement Disorders · doi:10.1002/mds.22028 · Cited by 344 · see citing works
Under the curve: Critical issues for elucidating D1 receptor function in working memory
Williams, G. V., & Castner, S. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.09.028 · Cited by 326 · see citing works
Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons
Jodoj, E., Chiang, C., & Aston-Jones, G. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00372-2 · Cited by 321 · see citing works
Koepsell, H., Schmitt, B. M., & Gorboulev, V. (2003) · Springer eBooks · doi:10.1007/s10254-003-0017-x · Cited by 318 · see citing works
Díaz-Mataix, L., Scorza, M. C., Bortolozzi, A. A., Tóth, M., Celada, P., & Artigas, F. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2999-05.2005 · Cited by 288 · see citing works
Self-citationIdentification and Characterization of a Novel Monoamine Transporter in the Human Brain*
Engel, K., Zhou, M.-Y., & Wang, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407913200 · Cited by 274 · see citing works
Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., & Cenci, M. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06556.x · Cited by 264 · see citing works
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Muñoz, A., Li, Q., Gardoni, F., Marcello, E. E., Qin, C., Carlsson, T., Kirik, D., Luca, M. D., Björklund, A., Bézard, E., et al. (2008) · Brain · doi:10.1093/brain/awn235 · Cited by 241 · see citing works
The activation of 5‐HT2A receptors in prefrontal cortex enhances dopaminergic activity
Bortolozzi, A. A., Díaz-Mataix, L., Scorza, M. C., Celada, P., & Artigas, F. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03485.x · Cited by 224 · see citing works
Self-citationDaws, L. C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.004 · Cited by 223 · see citing works
Self-citationLocus Coeruleus, A5 and A7 Noradrenergic Cell Groups
Aston‐Jones, G. (2004) · Elsevier eBooks · doi:10.1016/b978-012547638-6/50012-2 · Cited by 216 · see citing works
Cui, M., Aras, R. V., Christian, W. V., Rappold, P., Hatwar, M., Panza, J., Jackson-Lewis, V., Javitch, J., Ballatori, N., Przedborski, S., et al. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0900358106 · Cited by 213 · see citing works
Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3
Rappold, P. M., Cui, M., Chesser, A. S., Tibbett, J., Grima, J. C., Duan, L., Sen, N., Javitch, J. A., & Tieu, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115141108 · Cited by 209 · see citing works
Interaction of Organic Cations with a Newly Identified Plasma Membrane Monoamine Transporter
Engel, K., & Wang, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016832 · Cited by 200 · see citing works
Paracrine neurotransmission in the CNS: involvement of 5-HT
Bunin, M. A., & Wightman, R. M. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01410-1 · Cited by 187 · see citing works
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.012 · Cited by 187 · see citing works
Self-citationBaganz, N., Horton, R., Calderon, A., Owens, W. A., Munn, J., Watts, L., Koldzic-Zivanovic, N., Jeske, N., Koek, W., Toney, G., et al. (2008) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0800466105 · Cited by 171 · see citing works
Self-citationBacq, A., Balasse, L., Biała, G., Guiard, B. P., Gardier, A. M., Schinkel, A. H., Louis, F., Vialou, V., Martres, M., Chevarin, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.87 · Cited by 144 · see citing works
Catecholaminergic Brain Stem Regulatory Systems
Björklund, A., & Lindvall, O. (1986) · Comprehensive physiology · doi:10.1002/cphy.cp010403 · Cited by 130 · see citing works
Jaunarajs, K. L. E., Angoa‐Pérez, M., Kuhn, D. M., & Bishop, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.007 · Cited by 129 · see citing works
Expression and immunolocalization of the plasma membrane monoamine transporter in the brain
Dahlin, A., Li, X., Kong, W., Hevner, R. F., & Wang, J. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.01.072 · Cited by 127 · see citing works
Organic Cation Transporter 3 (Slc22a3) Is Implicated in Salt-Intake Regulation
Vialou, V., Amphoux, A., Zwart, R., Giros, B., & Gautron, S. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.5147-03.2004 · Cited by 109 · see citing works
l-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells
Stansley, B. J., & Yamamoto, B. K. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.010 · Cited by 107 · see citing works
Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor
Skolnick, P., Krieter, P. A., Tizzano, J. P., Basile, A. S., Popik, P., Czobor, P., & LIPPA, A. S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00123.x · Cited by 105 · see citing works
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.007 · Cited by 102 · see citing works
Self-citationHorton, R., Apple, D. M., Owens, W. A., Baganz, N. L., Cano, S., Mitchell, N. C., Vitela, M., Gould, G. G., Koek, W., & Daws, L. C. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5687-11.2013 · Cited by 89 · see citing works
Self-citationBortolozzi, A. A., Masana, M., Díaz-Mataix, L., Cortés, R., Scorza, M. C., Gingrich, J. A., Tóth, M., & Artigas, F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571000009x · Cited by 88 · see citing works
Self-citationBaganz, N., Horton, R., Martin, K. P., Holmes, A., & Daws, L. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2740-10.2010 · Cited by 79 · see citing works
Self-citationBishop, C., George, J. A., Buchta, W. C., Goldenberg, A. A., Mohamed, M., Dickinson, S. O., Eissa, S., & Jaunarajs, K. L. E. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08202.x · Cited by 75 · see citing works
Masana, M., Bortolozzi, A. A., & Artigas, F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000908 · Cited by 74 · see citing works
Self-citationFOX, M., JENSEN, C., GALLAGHER, P., & MURPHY, D. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.009 · Cited by 70 · see citing works
Duan, H., & Wang, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436972 · Cited by 64 · see citing works
The prefrontal cortex: a target for antipsychotic drugs
Artigas, F. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01455.x · Cited by 57 · see citing works
Self-citationDaws, L. C., Koek, W., & Mitchell, N. C. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn3001872 · Cited by 55 · see citing works
Self-citationKitaichi, K., Fukuda, M., Nakayama, H., et al. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.014 · Cited by 53 · see citing works
Navailles, S., Lagière, M., Contini, A., & Deurwaerdère, P. D. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400046e · Cited by 52 · see citing works
Self-citationThe nature of interactions involving prefrontal and striatal dopamine systems
Wilkinson, L. S. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100207 · Cited by 52 · see citing works
An anti-immobility effect of exogenous corticosterone in mice
Stone, E. A., & Lin, Y. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.10.045 · Cited by 51 · see citing works
Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review
Masana, M., Santana, N., Artigas, F., & Bortolozzi, A. A. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612805289872 · Cited by 30 · see citing works
Self-citationMonoaminergic Modulation of Cortical Excitability
Tseng, K.-Y., & Atzori, M. (2007) · Springer eBooks · doi:10.1007/978-0-387-72256-6 · Cited by 25 · see citing works
Björkholm, C., Jardemark, K. E., Marcus, M. M., Malmerfelt, A., Nyberg, S., Schilström, B., & Svensson, T. H. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.012 · Cited by 24 · see citing works
Feng, N., Lowry, C. A., Lukkes, J. L., Orchinik, M., Forster, G. L., & Renner, K. J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.02.044 · Cited by 23 · see citing works
Navailles, S., Carta, M., Guthrie, M., et al. (2011) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524911106040305 · Cited by 23 · see citing works
Self-citationRahman, Z., Ring, R., Young, K., Platt, B. J., Lin, Q., Schechter, L., Rosenzweig-Lipson, S., & Beyer, C. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.062 · Cited by 22 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Gasser PJ Chan C Ebben A Hill JE Robble M Wheeler DS Glucocorticoid-sensitive dopamine clearance in the nucleus accumbens: Organic cation transporter 3 as a mechanism for stress-induced enhancement of dopaminergic neurotransmission Proceedings of the tenth catecholamine symposium 2012 http://meetingassistant5.com/XICS2012/core_routines/view_abstract_no.php?abstractno=105
- Steinbush HW Björklund A Hökfelt T Kuhar MJ Serotonin-immunoreactive neurons and their projections in the CNS Classical transmitters and transmitter receptors in the CNS, Part II Handbook of chemical neuroanatomy 1984 Vol. 3 68 125 Elsevier Amsterdam
Cited by
Sorted by citations
Development of prefrontal cortex
Kolk, S. M., & Rakic, P. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01137-9 · Cited by 378 · see citing works
Hoyo-Alvarez, E., Arechavala-Lopez, P., Jiménez-García, M., Solomando, A., Alomar, C., Sureda, A., Moranta, D., & Deudero, S. (2022) · Aquatic Toxicology · doi:10.1016/j.aquatox.2021.106048 · Cited by 49 · see citing works
Serotonergic neuromodulation of synaptic plasticity
Higa, G. S. V., Viana, F. J. C., Francis-Oliveira, J., Cruvinel, E., Franchin, T. S., Marcourakis, T., Ulrich, H., & De Pasquale, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110036 · Cited by 29 · see citing works
Garcia, L. P., Witteveen, J. S., Middelman, A., van Hulten, J. A., Martens, G. J. M., Homberg, J. R., & Kolk, S. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1105-x · Cited by 28 · see citing works
Garcia, L. P., Van de Wijer, L., Hanswijk, S. I., Rando, J., Witteveen, J. S., Middelman, A., ter Heine, R., de Mast, Q., Martens, G. J. M., van der Ven, A. J. A. M., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114050 · Cited by 6 · see citing works
- Authors
- Hensler, J. G., Artigas, F., Bortolozzi, A., Daws, L. C., De Deurwaerdère, P., Milan, L., Navailles, S., & Koek, W.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Consejo Superior de Investigaciones Científicas (ES)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Hensler, Julie G.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2013
- Volume
- 68
- Pages
- 167-197
- ISSN
- 1054-3589 (ISSN-L)
- PMC
- PMC3902978
- OpenAlex
- W1822757692
- Cited by
- 73
- References
- 53
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 4 · 2018: 11 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 3
- FWCI
- 10.47
- Type
- book chapter
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Advances in pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Generalitat de Catalunya
- Centro de Investigación Biomédica en Red de Salud Mental
- Instituto de Salud Carlos III
- National Institute of Mental Health (R01MH064489, R01MH093320)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- catecholamines, serotonin, schizophrenia, cognitive impairment, negative symptoms, prefrontal cortex, 5-HT2A receptor, 5-HT1A receptor, Parkinson's disease, nigrostriatal dopaminergic neurons, L-DOPA, norepinephrine transporter, extracellular dopamine, antidepressant targets, organic cation transporters, plasma membrane monoamine transporter, monoamine neurotransmission
- MeSH terms
- Animals, Antidepressive Agents, Brain, Depression, Dopamine, Humans, Parkinson Disease, Schizophrenia, Serotonin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
